A Phase II Study of Venetoclax (ABT-199) in Combination With Cladribine and Low-Dose Cytarabine Alternating With Azacitidine Plus Venetoclax in Newly Diagnosed Monocytic AML and Active-Signaling Mutated AML
This study is testing a new combination of drugs to treat two specific types of newly diagnosed Acute Myeloid Leukemia (AML). By combining targeted therapy with chemotherapy, researchers hope to kill more cancer cells more effectively than current standard treatments.
This trial is for adults recently diagnosed with specific forms of AML—monocytic AML or AML with certain gene mutations. It is primarily designed for those who cannot or do not wish to undergo intensive chemotherapy induction.
Participants will receive a combination of medications, including venetoclax and chemotherapy drugs, in a rotating cycle. You will also have regular check-ups, which include blood tests, bone marrow biopsies, and heart scans to monitor your health and how the treatment is working.
The study is currently recruiting patients at clinical centers in Miami, Florida, and Portland, Oregon. Please speak with your doctor to see if one of these locations is accessible to you.
- 1Uses a combination of targeted drugs and chemotherapy to attack cancer cells.
- 2Specifically focused on patients who are not candidates for intensive chemotherapy.
- 3Involves regular monitoring procedures like bone marrow tests and heart imaging.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.